BiomX is a microbiome drug discovery company developing customized phage therapies that seek and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. We discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. BiomX was founded in 2015, trading on the NY stock exchange and has 115 employees in Israel and USA
biomx.com
Einstien 22 Ness Ziona